Atea Pharmaceuticals Inc (NAS:AVIR)
$ 4.48 -0.0050 (-0.11%) Market Cap: 357.32 Mil Enterprise Value: 101.95 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 24/100

Atea Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 11:00PM GMT
Release Date Price: $4.8 (-3.42%)
Hannah Temiloluwa Adeoye
JPMorgan Chase & Co, Research Division - Research Analyst

Great. Hi, everyone. Thanks so much for joining us here today. My name is Hannah Adeoye, and I'm an associate biotech analyst here at JPMorgan. Our next presenting company is Atea Pharmaceuticals, and presenting on the behalf of the company is CEO, J.P. Sommadossi, and some other members of the management team.

Just want to say we're going to be doing Q&A in the room after the presentation. So there should be some mic runners around the room. And for those who want to ask questions, simply raise your hand, and we'll get you a microphone. And if you are listening online or you want to ask a question online, you can also ask via the conference -- digital conference book.

And with that, I'm going to hand it off. Thank you. J.P.?

Jean;Pierre Sommadossi
Atea Pharmaceuticals, Inc. - Founder, Chairman, CEO & President

Thank you so much. And before I begin, I would like to thank JPMorgan for the opportunity to present today and give you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot